Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 250

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 250
---
 ​                                       |          — | ​ | ​    |     -30,330 |
| Noncash issuance of common stock to non-employee                                 | ​ | ​                                       |          — | ​ | ​    |           3 |
| Noncash initial fair value of warrant liability pursuant to private placement    | ​ | ​                                       |          — | ​ | ​    |  21,544,000 |
| Noncash initial fair value of derivative liability pursuant to private placement | ​ | ​                                       |          — | ​ | ​    |   6,140,000 |
| Noncash redemption of Series A Preferred Stock                                   | ​ | ​                                       |  6,586,033 | ​ | ​    |           — |
| Accrued Series A Convertible Preferred payments payable                          | ​ | ​                                       |  1,742,918 | ​ | ​    |   1,368,546 |
| Accretion of Series A convertible preferred stock to redemption value            | ​ | ​                                       |  9,099,230 | ​ | ​    |   1,153,846 |
| Accrual of Series convertible preferred stock dividends                          | ​ | ​                                       |    991,783 | ​ | ​    |     339,232 |

The accompanying Notes are an integral part of the Unaudited Condensed Consolidated Financial Statements.

F-36

#### PETROS PHARMACEUTICALS, INC.

### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
<div align='center'>(Unaudited)</div>

1) Nature of Operations, Basis of Presentation, Liquidity and Going Concern Nature of Operations Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the “Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), and certain subsidiaries of Petros and Neurotrope. Petros consists of wholly owned subsidiaries: Metuchen, Neurotrope, Timm Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”). The Company is engaged in the commercialization and development of Stendra®, a U